why choose us

First received: July 18, 2022

Clinical Trial: A Phase I Clinical Trial of Bevacizumab Injection

Study Status: Completed

Recruit Status: Completed

Condition: Rectal Cancer
Lung Cancer
Ovarian Cancer
Cervical Cancer
Glioblastoma

Study Type: Interventional


Official Title: A Randomized, Double-blind, Single Dose, Parallel Comparison of Bevacizumab Injection and Avastin ® Phase I Clinical Study on the Similarity of Pharmacokinetics and Safety of Traditional Chinese Medic

Brief Summary: Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor (bevacizumab) is Avastin produced by Zhengda Tianqing Pharmaceutical Group Co., Ltd Biological similar drugs. Its mechanism is to prevent VEGF from binding to its natural receptor VEGFR, inhibit the proliferation and activation of vascular endothelial cells, and play an anti angiogenesis and anti-tumor role by binding with VEGF. A randomized, double-blind, single dose, parallel comparison of bevacizumab injection…

Read more